Publications by authors named "Caroline R Medin"
Sarcoma is a complex and heterogeneous disease with a rapidly evolving treatment landscape. With a growing emphasis on neoadjuvant therapy as a way to improve surgical and oncologic outcomes, our approach to monitor treatment efficacy must also continue to evolve. This is paramount to both clinical trial design, where endpoints must accurately reflect disease outcomes, and individual patient, whose treatment response informs therapeutic decisions.
View Article and Find Full Text PDFArticle Synopsis
- A study examined health-related quality of life (HRQoL) for patients with cholangiocarcinoma (CCA), revealing limited data on how experimental therapies impact patients' well-being.
- Of the 208 patients surveyed, those in clinical trials or receiving targeted therapy experienced similar physical and emotional health as those who weren't, but reported greater financial burden.
- The findings suggest that while new therapies do not harm overall well-being, they are associated with higher costs and limited accessibility, emphasizing the need to improve access and reduce financial strain on patients.
Objective: This study aimed to enhance hepatocellular carcinoma (HCC) screening to achieve earlier diagnosis of patients with hepatitis C (HCV) cirrhosis in our Safety-Net population.
Background: Adherence to HCC screening guidelines at Safety-Net hospitals is poor. Only 23% of patients with HCC at our health system had a screening exam within 1-year of diagnosis and 46% presented with stage IV disease.
Background: Outcomes are thought to be worse in head and neck (H&N) melanoma patients. However, definitive evidence of inferior outcomes in H&N melanoma in the modern era is lacking. We sought to ascertain whether H&N melanomas carry a worse prognosis than melanomas of other sites.
View Article and Find Full Text PDF